Seattle Genetics Reports Encouraging Results From Phase I Lymphoma Trial
Posted on: Monday, 9 June 2008, 06:00 CDT
Seattle Genetics has announced encouraging results from the Phase I clinical trial of SGN-40 in patients with relapsed or refractory non-Hodgkin lymphoma.
A total of 50 patients with non-Hodgkin lymphoma were treated on the open label single-arm, dose-escalation study of SGN-40. Cohorts of patients received escalating doses of SGN-40 ranging from two milligrams per kilogram (mg/kg) to 8mg/kg. The median age was 62 years and patients had received a median of three prior therapies.
Out of 48 patients treated with SGN-40 who were evaluable for response across all dose levels, six patients achieved objective responses, including one complete response and five partial responses. A total of 13 patients had stable disease and 29 had progressive disease. Of the 22 patients on the trial with diffuse large B-cell lymphoma (DLBCL), a more aggressive type of non-Hodgkin lymphoma, four achieved an objective response. Overall, SGN-40 was well-tolerated with no maximum tolerated dose identified.
SGN-40 is a humanized monoclonal antibody being developed under a worldwide collaboration agreement with Genentech.
Thomas Reynolds, chief medical officer of Seattle Genetics, said: "The data support our ongoing development plan with Genentech, which includes multiple clinical trials of SGN-40 both as a single agent and in combination with standard treatment regimens for patients with DLBCL, the most common type of non-Hodgkin lymphoma."
Source: Datamonitor
Related Articles
- Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma
- New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
- Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
- Seattle Genetics Reports Multiple Complete and Partial Responses With SGN-35 in Patients With Lymphoma
- Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
- New Published Data Suggest "Dose Response With No Ceiling Effect"; Patient Outcomes Approach Those of Total Knee Replacement
- Dose-Response Relationships and Threshold Levels in Skin and Respiratory Allergy
- Commentary on Hormetic Dose-Response Relationships in Immunology: Occurrence, Quantitative Features of the Dose Response, Mechanistic Foundations, and Clinical Implications
- Lumiracoxib in the Treatment of Osteoarthritis, Rheumatoid Arthritis and Acute Postoperative Dental Pain: Results of Three Dose-Response Studies
- VELCADE(R) (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients With Non-Hodgkin's Lymphoma
 |
 |
User Comments (0)
RSS Feeds